Russell Investments Group Ltd. Increases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Russell Investments Group Ltd. increased its stake in Regeneron Pharmaceuticals by 6.9%, owning $93.08 million worth of shares as of the end of the first quarter.
• The company reported an EPS of $12.89 for the last quarter, exceeding estimates by $4.46, and a revenue increase of 3.6% year over year.
• Regeneron Pharmaceuticals announced a quarterly dividend of $0.88 per share, with a dividend yield of 0.6%, reflecting a payout ratio of 8.87%.

Russell Investments Group Ltd. boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 6.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 146,740 shares of the biopharmaceutical company's stock after purchasing an additional 9,532 shares during the period. Russell Investments Group Ltd. owned about 0.13% of Regeneron Pharmaceuticals worth $93,079,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Pinney & Scofield Inc. purchased a new position in Regeneron Pharmaceuticals in the fourth quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. lifted its position in shares of Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 31 shares during the last quarter. Costello Asset Management INC purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $27,000. Tompkins Financial Corp purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $32,000. Finally, Curat Global LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $32,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on REGN shares. UBS Group reaffirmed a "neutral" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Rothschild & Co Redburn started coverage on Regeneron Pharmaceuticals in a research report on Thursday. They set a "buy" rating and a $890.00 price target on the stock. Wall Street Zen cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. Wells Fargo & Company cut Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price target on the stock. in a research report on Friday, August 1st. Finally, Guggenheim upped their price target on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a research report on Friday, August 1st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $838.00.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN traded up $4.42 during trading on Thursday, reaching $565.97. The company's stock had a trading volume of 975,056 shares, compared to its average volume of 986,507. The stock has a market capitalization of $59.99 billion, a PE ratio of 14.26, a P/E/G ratio of 1.90 and a beta of 0.33. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The firm has a fifty day moving average of $542.46 and a 200 day moving average of $596.26. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. The business had revenue of $3,675,600 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. The company's quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the company earned $11.56 EPS. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.